CHICAGO — A trial of AstraZeneca’s heart drug Crestor was stopped early because the drug proved so effective that the study’s independent monitors felt it would be unethical to withhold treatment from half the volunteers, company officials said Monday.
“We’re excited,” says Lisa Nanfra of AstraZeneca.
The decision…
A CONSUMER group has asked US regulators to ban AstraZeneca’s cholesterol lowering drug, Crestor, citing reports of dangerous reactions and one death. Public Citizen, the campaign group founded by the independent presidential candidate Ralph Nader, is a persistent critic o…
CHESHIRE, England, November 1 /PRNewswire/ — New data published today in the American Journal of Cardiology add to a growing body of data that CRESTOR(R) (rosuvastatin calcium) may improve kidney function. The study, Effect of Rosuvastatin on C-Reactive Protein and Renal Function in Patients with Chronic Kidney Disease, shows that CRESTOR 10 mg has favourable anti-inflammatory effects in patients with chronic kidney disease and is supportive of potential accompany…
LONDON (AFP) — Anglo-Swedish pharmaceuticals giant AstraZeneca said Wednesday it would sue seven generic drug manufacturers in the United States to defend its patent of cholesterol treatment Crestor.
The world’s top pharmaceutical…
AstraZeneca, Europe’s second-largest drugmaker, has presented a comprehensive, 30-page response to the US Food and Drug Administration urging the agency to remove Public Citizen’s Health Research Group’s petition to ban its cholesterol-lowering drug Crestor (ro…
WILMINGTON, Del. — AstraZeneca’s drug Crestor has joined the elite ranks of cholesterol-fighting agents that also have been indicated to fight atherosclerosis.
The Food and Drug Administration recently approved Crestor as an adjunct to diet to slow the progression of atherosclerosis in patients with elevated cholesterol. An enzyme blocker in the statin class, Crestor is used along with a proper diet to help lower triglycerides and cholesterol in the blood. Atherosclerosis is the p…
The anti-cholesterol drug Crestor does not pose a greater risk of muscle damage than other drugs like it, the FDA said Monday, rejecting an advocacy group’s petition to withdraw the drug.
The Food and Drug Administration also said there is no convincing evidence to support the group’s contention that Crestor could cause serious kidney damage.
The decision is a boost for AstraZeneca, maker of the drug, w…
Crestor, the most powerful of the cholesterol-lowering statin drugs, causes more side effects than its weaker cousins and should be considered only after other drugs have been tried, researchers said Monday.
The study is the latest stumbling block for Crestor, launched by AstraZeneca in 2003, which had hoped it would compete with market leader Lipitor, made by Pfizer. Last year, it was one of several drugs FDA scientist David Graham said deserved further scrutiny, an…
